|
Lonza Reports Strong Momentum with Organic Growth of 8% Sales and 11% CORE EBITDA in H1 2018 • Outperformance in Pharma & Biotech in H1 2018 in sales, with margins up 270 bps, was combined with strong positive momentum in the newly formed Consumer Health division • Legacy Capsugel businesses, now well integrated into Lonza, exceeded expectations for performance and synergistic potential in H1 2018 • Growth drivers in Consumer & Resources Protection added to favorable momentum, but H1 2018 was negatively impacted by more mature, cyclical parts of the portfolio • Water business gained momentum in May and June with positive outlook from H2 2018 onward • Full-Year 2018 sales outlook was upgraded, and double-digit ROIC Mid-Term Guidance 2022 target was announced |
|
| aus der Diskussion: | Lonza - Lifescience-Konzern |
| Autor (Datum des Eintrages): | faultcode (25.07.18 12:30:02) |
| Beitrag: | 25 von 77 (ID:58297544) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |